A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-4082 in Healthy Overweight/Obese Participants
Latest Information Update: 03 Mar 2026
At a glance
- Drugs MK 4082 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Merck AG
Most Recent Events
- 27 Feb 2026 Planned initiation date changed from 27 Feb 2026 to 2 Mar 2026.
- 27 Feb 2026 Status changed from not yet recruiting to recruiting.
- 10 Feb 2026 New trial record